loratadine has been researched along with Disease Exacerbation in 3 studies
Loratadine: A second-generation histamine H1 receptor antagonist used in the treatment of allergic rhinitis and urticaria. Unlike most classical antihistamines (HISTAMINE H1 ANTAGONISTS) it lacks central nervous system depressing effects such as drowsiness.
loratadine : A benzocycloheptapyridine that is 6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridine substituted by a chloro group at position 8 and a 1-(ethoxycarbonyl)piperidin-4-ylidene group at position 11. It is a H1-receptor antagonist commonly employed in the treatment of allergic disorders.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (66.67) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Demoly, P | 1 |
| Dreyfus, I | 1 |
| Dhivert-Donnadieu, H | 1 |
| Mesbah, K | 1 |
| Bousquet, J | 1 |
| Bachert, C | 1 |
| Canonica, GW | 1 |
| Mullol, J | 1 |
| Van Cauwenberge, P | 1 |
| Jensen, CB | 1 |
| Fokkens, WJ | 1 |
| Ring, J | 1 |
| Keith, P | 1 |
| Gopalan, G | 1 |
| Lorber, R | 1 |
| Zuberbier, T | 1 |
| Buczyłko, K | 1 |
| Chwała, C | 1 |
| Zielińska-Bliźniewska, H | 1 |
| Wagner, A | 1 |
| Dzwonnik, A | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Multi-Centre, Double-Blind, Randomised Comparison Of The Effects Of Desloratadine (Aerius®) And Placebo In The Relief Of Nasal Symptom Scores In Subjects With Seasonal Allergic Rhinitis (Sar) To Cypress Pollen[NCT00867191] | Phase 4 | 233 participants (Actual) | Interventional | 2002-02-01 | Completed | ||
| Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, Multicenter/Multinational, Efficacy and Safety Study of Desloratadine 5 mg in the Treatment of Subjects With Allergic Rhinitis Who Meet the Criteria for Persistent Allergic Rhinitis (PER)[NCT00405964] | Phase 3 | 716 participants (Actual) | Interventional | 2006-09-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
AM/PM PRIOR (the participant's status over previous 12 hours) T5SS from the participant's daily diary averaged over treatment Days 1 to 85. AM/PM is the average of separate AM and PM evaluations. Scores were defined for T5SS as 0: no symptoms to 15: all severe symptoms. A two-way analysis of variance (ANOVA) model with treatment and site effects was used to examine the treatment difference. (NCT00405964)
Timeframe: Baseline and Days 1-85
| Intervention | units on a scale (Least Squares Mean) | |
|---|---|---|
| Baseline | Days 1-85 | |
| 5-mg Desloratadine Tablet | 9.63 | -4.50 |
| Placebo Tablet | 9.55 | -3.61 |
AM/PM PRIOR (the participant's status over previous 12 hours) T5SS from the participant's daily diary averaged over treatment Days 1 to 29. AM/PM is the average of separate morning (AM) and evening (PM) evaluations. Scores were defined for T5SS as 0: no symptoms to 15: all severe symptoms. A two-way analysis of variance (ANOVA) model with treatment and site effects was used to examine the treatment difference. (NCT00405964)
Timeframe: Baseline and Days 1-29
| Intervention | units on a scale (Least Squares Mean) | |
|---|---|---|
| Baseline | Days 1-29 | |
| 5-mg Desloratadine Tablet | 9.63 | -3.76 |
| Placebo Tablet | 9.55 | -2.87 |
The RQLQ-S was only completed for participants above 18 years of age. The RQLQ-S was not available for participants 12 to 17 years of age. This questionnaire asked questions pertaining to daily activities, sleep, non-nose eye symptoms, practical problems, nasal symptoms, eye symptoms, and emotions. The scale went from 0 (not troubled) to 6 (extremely troubled). A two-way analysis of variance (ANOVA) model with treatment and site effects was used to examine the treatment difference. (NCT00405964)
Timeframe: Baseline and Day 29
| Intervention | units on a scale (Least Squares Mean) | |
|---|---|---|
| Baseline | Day 29 | |
| 5-mg Desloratadine Tablet | 3.30 | -1.35 |
| Placebo Tablet | 3.15 | -0.95 |
2 trials available for loratadine and Disease Exacerbation
| Article | Year |
|---|---|
Desloratadine for the treatment of cypress pollen-induced allergic rhinitis.
Topics: Adult; Antigens, Plant; Cupressus; Disease Progression; Double-Blind Method; Female; France; Histami | 2009 |
Efficacy of desloratadine in persistent allergic rhinitis - a GA²LEN study.
Topics: Adult; Disease Progression; Female; Follow-Up Studies; Histamine H1 Antagonists, Non-Sedating; Human | 2010 |
1 other study available for loratadine and Disease Exacerbation
| Article | Year |
|---|---|
[The influence of desloratadine on course of intermittens allergic rhinitis].
Topics: Adolescent; Adult; Child; Child, Preschool; Conjunctivitis, Allergic; Disease Progression; Female; H | 2005 |